Area of research
Genetics · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Glioma Diagnosis and Treatment, MRI in cancer diagnosis, Radiomics and Machine Learning in Medical Imaging, and Advanced MRI Techniques and Applications.
CTNI-07. UNDERSTANDING COMMONLY REPORTED (≥15%) TREATMENT-RELATED ADVERSE EVENTS IN THE RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)
PATH-82. Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC
Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.
Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials
Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy
Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma
Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI
NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI)
Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images
Evaluation of High Ipsilateral Subventricular Zone Radiation Therapy Dose in Glioblastoma: A Pooled Analysis
Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma